Result description
Our solution employs forefront synthetic biology techniques to genetically engineer anaerobic, spore-forming bacteria with CRISPR-Cas9 gene editing and allelic exchange technology. These plasmid and antibiotic-free spores become delivery vehicles that secrete therpautics only at the core of hypoxic/necrotic tumours. In practice this means that we can administer the engineered chassis including the therapeutic compound to the patient.
Addressing target audiences and expressing needs
- Grants and Subsidies
- Other blended financing
- Venture Capital
A venture capital investment round to support Exomnis Biotech to the first in-human trial.
- Public or private funding institutions
- Private Investors
R&D, Technology and Innovation aspects
the development of our genetically modified stair is accomplished. we are now including therapeutical compounds to our chassis, and starting toxicology studies in order to be prepared for first in human trial.
the chassis we developed can be deployed to a wide range of applications. Cancer immunotherapy is the market we focus on currently, where potential to scale based on current immunotherapeutics that – due to too high toxicity – can not be deployed to market is enormous, since we believe that by improving the delivery method, the right dose of immunotherapeutic can be delivered to the right location, minimizing side effects and toxicity.
We have proven to be able to scale up our product and with constant quality reproduce our product and maintain a steady chain of quality on our product line, including several checks in the process. All methods are compiled in SOP’s and we are now moving forward to a first GMP batch of our product.
The added value of our delivery chassis to cancer immunotherapy is (scientifically) proven, has a direct impact on society since patient will benefit from treatment optimization. Economically our developed product will have and hold market value since we built – in parallel – both the scientific backbone to prove efficacy of our product but also safeguarded our IP in patent applications, in order to maintain economic value.
